CYTOMX THERAPEUTICS INC. - COMMON STOCK

CytomX Therapeutics to Present at Jefferies 2022 Global Healthcare Conference

01 Jun 2022 08:00:01 By Nasdaq GlobeNewswire

CytomX Therapeutics Announces First Patient Dosed with CX-904 in Phase 1 Study in Patients with Advanced Solid Tumors

26 May 2022 08:00:00 By Nasdaq GlobeNewswire

CytomX Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Update

05 May 2022 16:15:00 By Nasdaq GlobeNewswire

CytomX Therapeutics to Report First Quarter 2022 Financial Results on May 5, 2022

28 Apr 2022 08:00:02 By Nasdaq GlobeNewswire

CytomX Therapeutics Announces Retirement of John A. Scarlett, M.D. from Board of Directors

14 Apr 2022 16:15:00 By Nasdaq GlobeNewswire

CytomX Therapeutics Announces Retirement of Frederick W. Gluck from Board of Directors

23 Mar 2022 16:15:00 By Nasdaq GlobeNewswire

CytomX Therapeutics to Present Updated Preclinical Data for Conditionally Activated Cytokine Program at AACR Annual Meeting 2022

17 Mar 2022 08:00:01 By Nasdaq GlobeNewswire

CytomX Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results, and Provides Business Update

01 Mar 2022 16:15:00 By Nasdaq GlobeNewswire

CytomX Therapeutics to Present at Cowen 42nd Annual Healthcare Conference

28 Feb 2022 08:00:01 By Nasdaq GlobeNewswire

CytomX Therapeutics to Report Fourth Quarter and Full Year 2021 Financial Results on March 1, 2022

22 Feb 2022 08:00:02 By Nasdaq GlobeNewswire

CytomX Therapeutics Announces New Employment Inducement Grants

16 Feb 2022 08:00:01 By Nasdaq GlobeNewswire

CytomX Therapeutics Announces Promotion of Amy C. Peterson, M.D. to President and Chief Operating Officer

07 Feb 2022 09:00:01 By Nasdaq GlobeNewswire

CytomX Therapeutics Announces FDA Clearance of Investigational New Drug Application for CX-904 for the Treatment of Advanced Solid Tumors

19 Jan 2022 08:00:01 By Nasdaq GlobeNewswire

CytomX Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference

05 Jan 2022 08:00:03 By Nasdaq GlobeNewswire

CytomX Therapeutics Announces Preliminary Results for Ongoing Phase 2 Expansion Study of CX-2029, a First-in-Class Antibody-Drug Conjugate Candidate Targeting the Transferrin Receptor, CD71

20 Dec 2021 16:05:00 By Nasdaq GlobeNewswire

CytomX Therapeutics to Present at Upcoming November Investor Conferences

11 Nov 2021 08:00:01 By Nasdaq GlobeNewswire

CytomX Therapeutics Announces Third Quarter 2021 Financial Results and Provides Business Update

04 Nov 2021 16:15:01 By Nasdaq GlobeNewswire

CytomX Therapeutics to Present Preclinical Data for Conditionally Activated Cytokine Platform at Society for Immunotherapy of Cancer Annual Meeting

01 Nov 2021 08:00:01 By Nasdaq GlobeNewswire

CytomX Therapeutics to Announce Third Quarter 2021 Financial Results on November 4, 2021

28 Oct 2021 08:00:03 By Nasdaq GlobeNewswire

CytomX Therapeutics Announces New Employment Inducement Grants

18 Oct 2021 08:00:01 By Nasdaq GlobeNewswire